Hypertensive Blood Pressure in Adolescent Females With Polycystic Ovary Syndrome.

INTRODUCTION

Polycystic ovary syndrome is associated with hypertension in women, but few population studies have examined findings among adolescents. This retrospective study examines PCOS and hypertensive blood pressure in a large adolescent population receiving routine healthcare.

METHODS

Among females aged 13-17 years who had a well-child visit with systolic/diastolic blood pressure measured in a Northern California healthcare system (2013-2019), the outcome of hypertensive blood pressure (≥130/80 mmHg) was examined. Polycystic ovary syndrome was based on clinical diagnosis (ICD-9/10 256.4/E28.2) within 1 year of the visit. Overweight and obesity were defined by BMI 85th to <95th percentile and ≥95th percentile, respectively; 1.7% with underweight (<5th percentile) were excluded. Multivariable logistic regression was used to examine the association of polycystic ovary syndrome and hypertensive blood pressure, adjusting for age, race/ethnicity, BMI category, and estimated neighborhood deprivation index. Analyses were conducted in 2023-2024.

RESULTS

The cohort included 224,418 females (mean age 14.9±1.4 years; 34.3% non-Hispanic White, 30.1% Hispanic, 19.5% Asian/Pacific Islander, and 9.7% Black). Overall, 18.7% had overweight and 15.8% had obesity. The prevalence of hypertensive blood pressure was 7.2%, much higher for those with polycystic ovary syndrome (18.2%) versus no polycystic ovary syndrome (7.1%, p<0.001). In adjusted analyses, polycystic ovary syndrome was associated with 1.25-fold greater odds of hypertensive blood pressure (95% CI=1.10, 1.42). Similar findings were seen among the subset with obesity (OR=1.23 [95% CI=1.06, 1.42]).

CONCLUSIONS

Nearly 1 in 5 adolescents with polycystic ovary syndrome had hypertensive blood pressure. Polycystic ovary syndrome was associated with 25% increased adjusted odds of hypertensive blood pressure, emphasizing the importance of blood pressure surveillance in this population with higher cardiometabolic risk.